Print
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)
Prevention
People at high risk for prostate cancer due to an inherited mutation
Study Contact Information:
For additional information, please contact:
Olympia Price by phone: 857-238-3838
or by email: [email protected]
About the Study
This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.
What the Study Involves
Two groups of patients will be enrolled in this study:
- One group will enroll people who have an inherited mutation in one of the following genes: ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53
- The other study group will enroll people who do not have an inherited genetic mutation, but who do have a strong family history suggestive of increased risk for prostate cancer.
Both study groups will receive the same cancer screening tests:
- physical exam (digital rectal exam)
- prostate-specific antigen (PSA) test
- MRI of the prostate.
Study participants will be followed for up to 20 years.
Study Location
Massachusetts
- Boston, MA
Massachusetts General Hospital
Lead Researcher: Keyan Salari, MD, PhD
Study coordinator: Olympia Price: 857-238-3838 or [email protected]
This Study is Open To:
Men age 35-74 years old who meet the following criteria may be eligible:
- No prior diagnosis of prostate cancer
- Meets either group 1 or group 2 criteria:
- Group 1: has an inherited mutation in one of the following genes: ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53.
- Group 2: has a strong family history suggestive of high genetic risk for prostate cancer but with no inherited genetic mutation.
This Study is Not Open To:
Men are not eligible to participate if they:
- have had a prior diagnosis or treatment of prostate cancer
- are not able to undergo a prostate MRI or receive the MRI contrast agent
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.
